APLT News and Press, Applied Therapeutics Inc.

2024-07-01 07:21:15 ET Applied Therapeutics ( NASDAQ: APLT ) said the company was added to the Russell 3000 Index, effective after the U.S. market closed on June 28, 2024. Press Release Read the full article on Seeking Alpha For further details see: Appli...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was adde...

2024-06-11 10:45:04 ET Palo Alto Networks Inc (PANW) PANW is trading UP for the last 5 days, and it at trading at $313.28 with volume of 858,188 and a one day change of $4.23 (1.37%). Palo Alto Networks Inc has a 52-week low of 201.17 and a 52-week high of $380.84. The business's 50...

2024-05-29 03:19:57 ET Summary Applied Therapeutics is a clinical-stage biotech focused on treating symptoms of galactosemia in the central nervous system. Govorestat (AT-007) is in late-stage regulatory approval for galactosemia, with a PDUFA date set for November 2024. APLT ...

2024-05-28 10:23:38 ET Summary Applied Therapeutics develops govorestat for rare diseases and AT-001 for diabetic cardiomyopathy; both are aldose reductase inhibitors. Govorestat shows promise as a treatment for galactosemia by preventing galactose conversion. AT-001’s ...

2024-05-09 13:55:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Applied Therapeutics (NASDAQ: APLT ) just reported results for the first quarter of 2024. Applied Therapeutics reported earnings per share of -16 cents. This met the analy...

2024-05-09 07:59:34 ET More on Applied Therapeutics Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible Applied Therapeutics gets extension of FDA review for rare disease drug Applied Therapeutics GAAP EPS of -$1.42 beats by $0.02, revenue ...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025 Company discussing potential NDA submission under...

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate i...